Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children
- PDF / 224,031 Bytes
- 7 Pages / 547.087 x 737.008 pts Page_size
- 23 Downloads / 149 Views
(0123456789().,-volV) ( 01234567 89().,-volV)
ORIGINAL PAPER
Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children Qi Zhao
. Qian Hao
Received: 12 July 2020 / Accepted: 9 November 2020 Ó The Author(s) 2020
Abstract Purpose To investigate the clinical efficacy of 0.01% atropine in slowing the progression of myopia in children and to evaluate the influence of 0.01% atropine on secretion of basal tear and stability of tear film. Methods Eighty children aged 5–14 years with myopia, 40 were randomly divided into two groups consisting of those who received spectacles in addition to 0.01% atropine (SA group) and those who received only spectacles (S group). The remaining 40 children who were wearing orthokeratology (OK) lenses for 3 months were randomly divided into two groups comprising those who received OK lenses in addition to 0.01% atropine (OKA group) and those who received only OK lenses (OK group). Comprehensive ophthalmologic examinations, including slit-lamp examination, visual acuity testing, autorefraction, intraocular pressure, axial length (AL), corneal topography, Schirmer’s test, and tear film break-up time (TBuT), were performed before treatment and after every 3 months treatment. Results During the follow-up visits, evidently better spherical equivalent (SE) control over 3, 6 and 12 months was observed in the SA and OKA groups
compared with the S and OK groups. The AL over 3, 6, and 12 months was evidently inhibited in the SA and OKA groups compared with the S and OK groups. No statistically significant differences in Schirmer’s test and TBuT results were observed between the S and SA groups and between the OK and OKA groups. However, statistically significant differences were found in TBuT results between before treatment and after 3 months treatment in the OK group (P \ 0.05, paired t test) and the OKA group (P \ 0.05, paired t test). Conclusions 0.01% atropine can effectively control myopia progression and axial elongation regardless of combined treatment with spectacles or OK lenses. And 0.01% atropine has no evident effect on Schirmer’s test and TBuT results; however, researchers also found that Schirmer’s test and TBuT results showed a tendency to reduce after treatment with 0.01% atropine. Keywords Children
0.01% atropine Myopia progression
Introduction Q. Zhao (&) Q. Hao Department of Ophthalmology, The Second Hospital of Dalian Medical University, 467 Zhongshan Road, Shahekou District, Dalian, People’s Republic of China e-mail: [email protected]
Myopia is a refractive error in which the refractive power is too large relative to the axial length of the eye. That is to say, in the static state of adjustment,
123
Int Ophthalmol
external parallel light enters the eye and focuses before the photoreceptor layer of the retina, resulting in blurred far vision and clear near vision. Once myopia is formed, it will be irreversible. Nowadays, myopia is a common refractive error in children [1]. The prevalence of pediatric myopia reached to very high level
Data Loading...
